AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05284955
Drug: Standard heart failure medical therapy
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heart failure medical therapy as recommended by guidelines.
Trial: NCT04399343
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
Trial: NCT06176820
Drug: Vaginal Gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
Trial: NCT06176820
Drug: Vaginal lubricant
RxNorm normalized name: Film, Multi Ingredient Vaginal Film [VCF VAGINAL LUBRICANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
Trial: NCT06139991
Drug: Treatment B (BDA MDI HFA)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
Trial: NCT05614518
Drug: Technetium[99mTc] Methylenediphosphonate Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject was given 10-25 mCi intravenously. Images were collected 3-6 hours after injection.
Trial: NCT04954326
Drug: Lyophilized S95014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.
Trial: NCT05306249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the MCT oil placebo without CBD until the end of week 12.
Trial: NCT06156059
Drug: Oral Bedtime Melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral suspension or capsule given at bedtime
Trial: NCT06156059
Drug: Placebo suspension or capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indistinguishable suspension or capsule
Trial: NCT05771584
Drug: AST-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg
Trial: NCT05011916
Drug: KDR2-2 suspension eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
Trial: NCT06486337
Drug: CMOP±R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
Trial: NCT04908345
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used at induction and during surgery
Trial: NCT05828836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily
Trial: NCT04976647
Drug: HLX10+chemo
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
Trial: NCT04976647
Drug: HLX10+HLX07+chemo
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
Trial: NCT04393311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ulinastatin administered via IV infusion
Trial: NCT04829123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by subcutaneous injection in the abdomen
Trial: NCT03417921
Drug: ABTL0812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABTL0812 in combination with gemcitabine and nab-paclitaxel
Trial: NCT06489093
Drug: NSF
RxNorm normalized name: Transferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
Trial: NCT06489093
Drug: SDF+KI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
Trial: NCT00793247
Drug: PRU-PLA-PRU-PLA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00793247
Drug: PLA-PRU-PLA-PRU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00793247
Drug: PLA-PRU-PRU-PLA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00793247
Drug: PRU-PLA-PLA-PRU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04103554
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care used for treating BP
Trial: NCT05088967
Drug: IBI110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R2PD d1 IV every 3 weeks
Trial: NCT06342336
Drug: HS-IT101 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Trial: NCT05143164
Drug: Gentamicin Sulfate, Topical
RxNorm normalized name: Gentamicin Sulfate, Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of gentamicin to exit site daily
Trial: NCT05664789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT04702516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
Trial: NCT06146777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05570812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (4-week ramp, 4-week steady dosing)
Trial: NCT05492812
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin
Trial: NCT04553263
Drug: Contrave 8Mg-90Mg Extended-Release Tablet
RxNorm normalized name: Contrave 8mg-90mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
Trial: NCT01539174
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01539174
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03826524
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine 1mg 1:10000 (10cc) per dose
Trial: NCT00417053
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00417053
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05518695
Drug: BAT2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
Trial: NCT05563389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo arm
Trial: NCT05694975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total dosage of placebo(5% glucose) for the control group is 24 g per day.
Trial: NCT05258747
Drug: Lynparza® (olaparib) tablets 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
Trial: NCT04974814
Drug: Rosuvastatin 40mg
RxNorm normalized name: ROSUVASTATIN 40MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
Trial: NCT05613387
Drug: ZP8396
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used.
Trial: NCT04853823
Drug: PDC-APB
RxNorm normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDC-APB Intra-muscular Injection
Trial: NCT04781270
Drug: mFOLFOXIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
Trial: NCT04781270
Drug: mFOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
Trial: NCT04887506
Drug: TAVT-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
Trial: NCT05508204
Drug: BION-1301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution for SC injection administered as a single dose
Trial: NCT05613387
Drug: Drug: Placebo (ZP8396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin).
Trial: NCT04761952
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: daily orally
Trial: NCT05638737
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831
Trial: NCT04037241
Drug: NLIR+FU/FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: systemic chemotherapy regimen
Trial: NCT04037241
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: systemic chemotherapy regimen
Trial: NCT05121389
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
Trial: NCT03863145
Drug: CB-03-10
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-03-10, 100 mg capsule for oral use
Trial: NCT06311903
Drug: High dose of Norepinephrine (NE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received NE gradually till reach high dose (≥0.3 μg/kg/min).
Trial: NCT04977570
Drug: SYHA1805 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of SYHA1805 with three pre-designed doses
Trial: NCT04977570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of placebo with matching doses
Trial: NCT05759962
Drug: LQT-1213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Trial: NCT05624723
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB054707 75 mg will be administered orally
Trial: NCT06456489
Drug: Solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg methylprednisolone intravenous pulse on 2 consecutive days
Trial: NCT05575297
Drug: Methotrexate Sodium
RxNorm normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate oral administration alone
Trial: NCT04953962
Drug: CBP501 (25)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m2
Trial: NCT05428449
Drug: GT20029 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
Trial: NCT05428449
Drug: GT20029 Gel Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
Trial: NCT04415853
Drug: Lerotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 50 mg/capsule and 150 mg/capsule
Trial: NCT04591379
Drug: Influenza Vaccines
RxNorm normalized name: Influenza vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral application of an unattenuated influenza vaccine
Trial: NCT04845399
Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
Trial: NCT05318846
Drug: HRS4800 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing frequency: single dose; Route of administration: oral
Trial: NCT05318846
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing frequency: single dose; Route of administration: oral
Trial: NCT00046306
Drug: Antioxidants
RxNorm normalized name: E Complex with Antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06470477
Drug: Guideline-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.
Trial: NCT05518071
Drug: CRGD-ZW800-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
Trial: NCT00001039
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05851924
Drug: NALIRIFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle
Trial: NCT05492305
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
Trial: NCT05238831
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05407285
Drug: cannabis 0 mg, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Trial: NCT05262452
Drug: FOLFIRINOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a chemotherapy regimen for treatment of advanced pancreatic cancer~* FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~* F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~* IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~* OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis
Trial: NCT05407285
Drug: Cannabis 20 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Trial: NCT05317442
Drug: Fespixon Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks
Trial: NCT05492851
Drug: Synvisc-One 48 MG in 6 ML Prefilled Syringe
RxNorm normalized name: Synvisc-One 48 MG in 6 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection to treat knee osteoarthritis
Trial: NCT05492851
Drug: Monovisc 88 MG Per 4 ML Prefilled Syringe
RxNorm normalized name: Monovisc 88 MG per 4 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection to treat knee osteoarthritis
Trial: NCT05292053
Drug: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
RxNorm normalized name: TRELEGY ELLIPTA 100mcg-62.5mcg-25mcg/actuation Powder for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
Trial: NCT04014244
Drug: Corticosteroid vs. Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
Trial: NCT05742230
Drug: blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment
Trial: NCT05408923
Drug: (0.05% chlorhexidine gluconate (CHG) in sterile water)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
Trial: NCT04758234
Drug: LY3549492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04758234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05034068
Drug: 0.15% bezaydamine hydrochloride.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
Trial: NCT06018727
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 20 mg capsule will be administered orally.
Trial: NCT06018727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebos will be administered orally.
Trial: NCT04592159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oromucosal spray
Trial: NCT06413953
Drug: TQB3107 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3107 tablets is protein inhibitor that inhibit tumor cell proliferation, and induce apoptosis, thereby exerting anti-tumor effects.